These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 25092414)
1. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics. Murray JM; Thompson AM; Vitsky A; Hawes M; Chuang WL; Pacheco J; Wilson S; McPherson JM; Thurberg BL; Karey KP; Andrews L Mol Genet Metab; 2015 Feb; 114(2):217-25. PubMed ID: 25092414 [TBL] [Abstract][Full Text] [Related]
2. Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease. Ziegler RJ; Brown C; Barbon CM; D'Angona AM; Schuchman EH; Andrews L; Thurberg BL; McPherson JM; Karey KP; Cheng SH Mol Genet Metab; 2009 May; 97(1):35-42. PubMed ID: 19231265 [TBL] [Abstract][Full Text] [Related]
3. Liposome-targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation. Aldosari MH; de Vries RP; Rodriguez LR; Hesen NA; Beztsinna N; van Kuilenburg ABP; Hollak CEM; Schellekens H; Mastrobattista E Eur J Pharm Biopharm; 2019 Apr; 137():185-195. PubMed ID: 30818011 [TBL] [Abstract][Full Text] [Related]
5. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Dodge JC; Clarke J; Treleaven CM; Taksir TV; Griffiths DA; Yang W; Fidler JA; Passini MA; Karey KP; Schuchman EH; Cheng SH; Shihabuddin LS Exp Neurol; 2009 Feb; 215(2):349-57. PubMed ID: 19059399 [TBL] [Abstract][Full Text] [Related]
6. Comparative effects of recombinant acid sphingomyelinase administration by different routes in niemann-pick disease mice. Bae JS; Jang KH; Schuchman TR; Jin HK Exp Anim; 2004 Oct; 53(5):417-21. PubMed ID: 15516789 [TBL] [Abstract][Full Text] [Related]
7. Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse. Yang WW; Dodge JC; Passini MA; Taksir TV; Griffiths D; Schuchman EH; Cheng SH; Shihabuddin LS Exp Neurol; 2007 Oct; 207(2):258-66. PubMed ID: 17686472 [TBL] [Abstract][Full Text] [Related]
8. Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. Miranda SR; He X; Simonaro CM; Gatt S; Dagan A; Desnick RJ; Schuchman EH FASEB J; 2000 Oct; 14(13):1988-95. PubMed ID: 11023983 [TBL] [Abstract][Full Text] [Related]
9. Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency). McGovern MM; Wasserstein MP; Kirmse B; Duvall WL; Schiano T; Thurberg BL; Richards S; Cox GF Genet Med; 2016 Jan; 18(1):34-40. PubMed ID: 25834946 [TBL] [Abstract][Full Text] [Related]
10. AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Barbon CM; Ziegler RJ; Li C; Armentano D; Cherry M; Desnick RJ; Schuchman EH; Cheng SH Mol Ther; 2005 Sep; 12(3):431-40. PubMed ID: 16099409 [TBL] [Abstract][Full Text] [Related]
12. Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A. Buccinnà B; Piccinini M; Prinetti A; Scandroglio F; Prioni S; Valsecchi M; Votta B; Grifoni S; Lupino E; Ramondetti C; Schuchman EH; Giordana MT; Sonnino S; Rinaudo MT J Neurochem; 2009 Apr; 109(1):105-15. PubMed ID: 19187445 [TBL] [Abstract][Full Text] [Related]
13. Sphingomyelin 16:0 is a therapeutic target for neuronal death in acid sphingomyelinase deficiency. Gaudioso Á; Jiang X; Casas J; Schuchman EH; Ledesma MD Cell Death Dis; 2023 Apr; 14(4):248. PubMed ID: 37024473 [TBL] [Abstract][Full Text] [Related]
14. Identification of novel biomarkers for Niemann-Pick disease using gene expression analysis of acid sphingomyelinase knockout mice. Dhami R; Passini MA; Schuchman EH Mol Ther; 2006 Mar; 13(3):556-64. PubMed ID: 16214420 [TBL] [Abstract][Full Text] [Related]
15. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency. Thurberg BL; Wasserstein MP; Jones SA; Schiano TD; Cox GF; Puga AC Am J Surg Pathol; 2016 Sep; 40(9):1232-42. PubMed ID: 27340749 [TBL] [Abstract][Full Text] [Related]
16. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. Pérez-Cañamás A; Benvegnù S; Rueda CB; Rábano A; Satrústegui J; Ledesma MD Mol Psychiatry; 2017 May; 22(5):711-723. PubMed ID: 27620840 [TBL] [Abstract][Full Text] [Related]
17. An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease. He X; Chen F; Gatt S; Schuchman EH Anal Biochem; 2001 Jun; 293(2):204-11. PubMed ID: 11399033 [TBL] [Abstract][Full Text] [Related]
18. [Study of acid sphingomyelinase in Niemann-Pick mice]. Sakiyama T; Kitagawa T Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):484-90. PubMed ID: 2024027 [No Abstract] [Full Text] [Related]
19. Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. He X; Miranda SR; Xiong X; Dagan A; Gatt S; Schuchman EH Biochim Biophys Acta; 1999 Jul; 1432(2):251-64. PubMed ID: 10407147 [TBL] [Abstract][Full Text] [Related]
20. Improvement of biochemical and behavioral defects in the Niemann-Pick type A mouse by intraventricular infusion of MARCKS. Trovò L; Stroobants S; D'Hooge R; Ledesma MD; Dotti CG Neurobiol Dis; 2015 Jan; 73():319-26. PubMed ID: 25251606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]